About this episode
Pfizer’s effort to join the weight-loss drug craze just hit a major setback. Patients are quitting its trial after experiencing unpleasant side effects. We’ll bring you the details, and the stock reaction.
Plus, our Retail Ecosystem series concludes with a look at luxury stocks. Is the high-end consumer still buying, or spending money elsewhere on things like experiences? We’ll ask an industry insider.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Get every episode summarized
Each time Power Lunch publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Power Lunch
Fed holds rates steady 4/29/26
Power Lunch
Stocks sell off as OpenAI report hits market 4/28/26
Power Lunch
Market waits for Big Tech earnings this week 4/27/26
Power Lunch
Semiconductor stocks keep surging 4/24/26
Power Lunch